泊沙康唑
医学
伏立康唑
指南
重症监护医学
支气管肺泡灌洗
曲菌病
内科学
卡斯波芬金
病理
皮肤病科
免疫学
抗真菌
肺
作者
Andrew J. Ullmann,José María Aguado,Sevtap Arıkan-Akdağlı,David W. Denning,Andreas H. Groll,Katrien Lagrou,Cornelia Lass‐Flörl,Russell E. Lewis,Patricia Muñóz,Paul E. Verweij,Adilia Warris,Florence Ader,Murat Akova,Maiken Cavling Arendrup,Rosemary A. Barnes,Catherine Beigelman‐Aubry,Stijn Blot,Emilio Bouza,Roger J. M. Brüggemann,Dieter Buchheidt
标识
DOI:10.1016/j.cmi.2018.01.002
摘要
The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numerous recommendations, a few are summarized here. Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct microscopy, preferably using optical brighteners, histopathology and culture are strongly recommended. Serum and BAL galactomannan measures are recommended as markers for the diagnosis of IA. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing should be performed in patients with invasive disease in regions with resistance found in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents for first-line treatment of pulmonary IA, whereas liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. We strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging.
科研通智能强力驱动
Strongly Powered by AbleSci AI